Prelude Therapeutics Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.1M | $7.0M | — | — | — |
| Research and development | $94.3M | $118.0M | $103.4M | $92.9M | $86.8M |
| Operating expenses | $116.7M | $146.7M | $132.3M | $123.5M | $113.7M |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M |
| Balance Sheet | |||||
| Cash and equivalents | $35.3M | $12.5M | $25.3M | $30.6M | $31.8M |
| Current assets | $105.7M | $135.9M | $235.6M | $204.4M | $295.1M |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M |
| Current liabilities | $53.0M | $25.6M | $21.8M | $21.7M | $19.2M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M |
| Stockholders' equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M |
| Depreciation and amortization | $1.7M | $1.8M | $1.2M | $1.3M | $915,000 |
| Stock-based compensation | $11.9M | $21.3M | $25.6M | $25.1M | $20.9M |
| Capital expenditure | $67,000 | $764,000 | $3.5M | $3.0M | $2.3M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M | -$85.9M |
Shares outstanding 79.6M · Free float 62.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.